Sentinel Lymphadenectomy for Early-Stage Cervical Cancer — the New Standard?
Mené sur 838 patientes atteintes d'un cancer du col utérin (durée médiane de suivi : 62,8 mois), cet essai randomisé multicentrique évalue la non infériorité, du point de vue de la survie sans maladie à 3 ans, d'une biopsie du ganglion sentinelle seule par rapport à une biopsie du ganglion sentinelle en combinaison avec une lymphadénectomie
Cervical cancer remains a global health problem, with more than 600,000 new cases and more than 340,000 deaths estimated annually.1 Radical hysterectomy with pelvic lymphadenectomy has remained the cornerstone of therapy for patients with early-stage cervical cancer since the early 1900s. Although the procedure achieves excellent disease control, it is associated with substantial complications, including lymphedema, which can have a profound effect on quality of life. Sentinel-lymph-node biopsy has the potential to mitigate complications without compromising oncologic outcomes. In this issue of the Journal, Tu and colleagues2 report results from the PHENIX (Lymph-Node Dissection in Cancer of the Cervix) trial, . . .
New England Journal of Medicine , éditorial, 2025